A PREDICTIVE BIOMARKER FOR METASTATIC RELAPSE IN EARLY- STAGE BREAST AND COLON CANCER

PULSALYS



06 Novembre 2015

Partager sur facebook Partager sur twitter Partager sur linkedin Partager sur google+

Fields

Biology / Medical

Sectors

Health

DESCRIPTION
The laboratory has identified a new protein biomarker, highly specific for breast and colon cancer, which helps predicting the risk for the cancer to relapse and/or to develop metastases.
The analysis of this marker expression by TMA (Tissue MicroArrays) immunohistochemistry on breast and colon cancer samples, has demonstrated that colorectal tumors showing more than 50% positively-stained cells or breast tumors showing less than 50% positively-stained cells are related to high risks of relapse, either local or metastatic.

STAGE OF DEVELOPMENT
Analysis of TMA breast & colorectal cancer samples with RT-QPCR and immunohistochemistry (cancer samples considered of good prognosis using classical markers – Gleason 1 to 4 for colon cancer and SBR 1 to 3 for breast cancer

INTELLECTUAL PROPERTY
Patent pending in EP
Priority date: October, 3rd, 2011 (FR1158910)

ADVANTAGES / NOVELTY
The addition of a single protein marker to predict metastatic progression of good prognosis cancers is:
• Simpler & faster to perform
• Less expensive

APPLICATIONS
• Breast & colorectal cancer prognosis
• Cancer clinical therapeutic decision

COLLABORATION TYPE
PULSALYS looks for industrial partners and offers to grant patent license.

CONTACT
Daphne THOMAS
Tech Transfer Officer - Health
Tél. : +33 (0) 4 26 23 56 78
daphne.thomas@pulsalys.fr

Download the offer Download the offer

Newsletter